2-Bromo-3-(tert-butyl)pyridine | 1211521-35-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 2-Bromo-3-(tert-butyl)pyridine
• 英文别名: 2-bromo-3-tert-butylpyridine
• CAS: 1211521-35-5
• 化学式: C₉H₁₂BrN
• 分子量: 214.1
• InChiKey: GNKSIAKAPOWLMH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  12.9
• 氢给体数：
  0
• 氢受体数：
  1

文献信息

• UREA-CONTAINING PEPTIDES AS INHIBITORS OF VIRAL REPLICATION
  申请人：Chen Dawei

  公开号：US20090082261A1

  公开（公告）日：2009-03-26

  The invention provides compounds urea-containing peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables T, R 1 -R 9 , J, L, M, Y, Z, m, n, and t are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain urea-containing peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more urea containing peptides compounds and one or more pharmaceutically acceptable carriers, excipients, or diluents. Such pharmaceutical compositions may contain a urea containing peptides compound as the only active agent or may contain a combination of a urea containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.

  本发明提供了含有尿素的多肽化合物，其结构如式I所示，以及它们的药物盐和 hydrates（水合物）。 变量T，R1-R9，J，L，M，Y，Z，m，n和t在此文中定义。式I中的某些化合物作为抗病毒剂是有用的。本文中公开的某些含尿素的多肽化合物是病毒复制的强效和/或选择性抑制剂，尤其是丙型肝炎病毒复制。本发明还提供了包含一个或多个含尿素多肽化合物以及一个或多个药物可接受载体、辅料或稀释剂的药物组合物。这样的药物组合物可以仅含有一个含尿素多肽化合物作为唯一的活性成分，也可以包含一个含尿素多肽化合物与一个或多个其他药物活性成分的组合。本发明还提供了治疗哺乳动物中病毒感染的方法，包括丙型肝炎感染。
• PYRIDONE COMPOUNDS AND AGRICULTURAL AND HORTICULTURAL FUNGICIDES CONTAINING THE SAME AS ACTIVE INGREDIENTS
  申请人：MITSUI CHEMICALS AGRO, INC.

  公开号：US20200172486A1

  公开（公告）日：2020-06-04

  Provided are a pyridone compound represented by Formula (1): wherein R1 represents a C1-C6 alkyl group which may be substituted, etc., R2 represents a halogen atom, a cyano group, etc., R3 and R4 are independent to each other, and each represents a hydrogen atom, a C1-C6 alkyl group which may be substituted, etc., or in combination with the nitrogen atom to which they are bonded form a pyrrolidinyl group, a piperidinyl group, etc., which may be substituted, Y represents a phenyl group which may be substituted, etc., X represents an oxygen atom or a sulfur atom, and an agricultural and horticultural fungicide containing the same as an active ingredient.

  提供的是由化学式（1）表示的吡啶酮化合物： 其中 R1代表一个可能被取代的C1-C6烷基，等等， R2代表一个卤素原子，一个氰基，等等， R3和R4彼此独立，每个代表一个氢原子，一个可能被取代的C1-C6烷基，等等，或者与它们结合的氮原子形成一个可能被取代的吡咯啉基团，一个哌啶基团，等等， Y代表一个可能被取代的苯基，等等， X代表一个氧原子或硫原子， 以及含有该化合物作为活性成分的农业和园艺用杀菌剂。
• 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION
  申请人：Phadke Avinash

  公开号：US20090048297A1

  公开（公告）日：2009-02-19

  The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables R 1 -R 9 , R 16 , R 18 , R 19 , n, M, n, M, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide compounds and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain 4-amino-4-oxobutanoyl peptide compound as the only active agent or may contain a combination of 4-amino-4-oxobutanoyl peptide containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.

  该发明提供了Formula I的4-氨基-4-氧代丁酰肽化合物及其药用盐和水合物。变量R1-R9、R16、R18、R19、n、M和Z在此处定义。Formula I的某些化合物可用作抗病毒剂。本文披露的某些4-氨基-4-氧代丁酰肽化合物是有效和/或选择性抑制病毒复制的药物，特别是乙型肝炎病毒的复制。该发明还提供含有一种或多种4-氨基-4-氧代丁酰肽化合物和一种或多种药用载体的药物组合物。这种药物组合物可能仅含有4-氨基-4-氧代丁酰肽化合物作为唯一活性剂，也可能含有一种或多种其他药用活性剂与含有4-氨基-4-氧代丁酰肽的肽化合物的组合。该发明还提供了治疗哺乳动物病毒感染的方法，包括乙型肝炎感染。
• CYCLIC CARBOXAMIDE COMPOUNDS AND ANALOGUES THEREOF AS OF HEPATITIS C VIRUS
  申请人：Zhang Suoming

  公开号：US20100124545A1

  公开（公告）日：2010-05-20

  The invention provides cyclic carboxamide compounds and analogues thereof of Formula I and the pharmaceutically salts and hydrates thereof. The variables R, R 1 , R 6 -R 8 , R 16 , R 18 , R 19 , M, n, T, Y, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain cyclic carboxamide compounds and cyclic carboxamide analogues disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more cyclic carboxamide compounds or cyclic carboxamide analogues and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain a cyclic carboxamide compound or cyclic carboxamide analogue as the only active agent or may contain a combination of a cyclic carboxamide compound or cyclic carboxamide analogue and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections.

  本发明提供了公式I的环状羧酰胺化合物及其类似物，以及其药物盐和水合物。其中，变量R、R1、R6-R8、R16、R18、R19、M、n、T、Y和Z在此定义。公式I的某些化合物可用作抗病毒剂。本发明所披露的某些环状羧酰胺化合物和环状羧酰胺类似物是有效和/或选择性抑制病毒复制的抑制剂，尤其是乙型肝炎病毒复制的抑制剂。本发明还提供了含有一个或多个环状羧酰胺化合物或环状羧酰胺类似物和一个或多个药用载体的药物组合物。这样的药物组合物可以仅包含一个环状羧酰胺化合物或环状羧酰胺类似物作为唯一活性剂，也可以包含一个环状羧酰胺化合物或环状羧酰胺类似物和一个或多个其他药用活性剂的组合。本发明还提供了治疗病毒感染，包括乙型肝炎感染的方法。
• QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
  申请人：Beshore Douglas C.

  公开号：US20120196845A1

  公开（公告）日：2012-08-02

  The present invention is directed to quinolinone-pyrazolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

  本发明涉及公式（I）的喹啉酮-吡唑酮化合物，它们是M1受体正向变构调节剂，可用于治疗M1受体参与的疾病，如阿尔茨海默病、精神分裂症、疼痛或睡眠障碍。本发明还涉及包括上述化合物的制药组合物，以及在治疗M1受体介导的疾病中使用上述化合物和组合物的方法。